India mulling plans to build bulk drug manufacturing capacity

The Indian government is expected to announce new strategies to bolster its bulk drug manufacturing capacity as part of an effort to reduce the country's dependency on Chinese API imports.

India currently imports between 70% and 80% of its bulk drugs from China, a government official told The Economic Times.

"There was a time when India was producing bulk drugs in a big way and now nothing," Pharmaceuticals Secretary V.K. Subburaj said. "We will shortly come out with strategies to improve our bulk drug capacity in India."

Strategies developed by a government-appointed committee are currently under review by the Department of Pharmaceuticals, which is expected to release its recommendations soon, Subburaj said. Those recommendations are expected to become part of a proposed bulk drug pharma policy.

Also under consideration is the revival of the Hindustan Antibiotics facility in Pune, which is known as the first plant in the country to commercially produce antibiotics.

"In 10 years' time, our bulk drug dependence on China should reduce significantly," Subburaj said.

- see The Economic Times story

Related Articles:
Cadila Pharmaceuticals API plant slapped for faulty follow-up on stinking APIs
Dr. Reddy's, Endo benefit from Ranbaxy manufacturing shortfalls
India's Wockhardt profit freefalls as FDA bans devastate U.S. sales
Zydus Cadila bottling flop sparks another Indian recall
FDA Commissioner Hamburg heads for India to talk about quality manufacturing

Suggested Articles

McCallum was hit with a warning letter from the FDA for testing issues with its products and failing to keep appropriate records.

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.